In metastatic GC patients, mutations were frequently detected in TP53 (43.9%), PIK3CA (12.1%), SMARCB1 (8.1%), ALK (7.3%), and PTEN (6.5%), as shown in Supplementary Fig 1A and in our previous study.11 For NSCLC, TP53 (90.4%), EGFR (48.9%), SMARCB1 (8.5%), PTEN (7.4%), and KRAS (7.4%) were frequently mutated (Supplementary Fig 1B). Here, PIK3CA is linked to non-small cell lung carcinoma.